Ann Rheum Dis 1998;57:110-113 ( February )

Concise reports

Effects of moderate renal insufficiency on pharmacokinetics of methotrexate in rheumatoid arthritis patients F Bressolle,^a C Bologna,^b J M Kinowski,^a J Sany,^b B Combe^b

^a Laboratoire de Pharmacocinétique, Faculté de Pharmacie, Montpellier, and Laboratoire de Pharmacocinétique, CHU Carémeau, Nîmes, France, ^b Fédération de Rhumatologie, CHU Lapeyronie, Montpellier, France

Correspondence to: Professor B Combe, Fédération de Rhumatologie, CHU Lapeyronie, 34295 Montpellier Cedex 5, France.

Accepted for publication 6 January 1998

OBJECTIVESTo determine the effects of impaired renal function on the pharmacokinetics of methotrexate (MTX) in rheumatoid arthritis (RA) patients.
METHODS77 RA patients were included in this study. MTX was administered intramuscularly (7.5 to 15 mg). Subjects were divided into four groups, according to their creatinine clearance (CL_CR); group 1: CL_CR lower than 45 ml/min; group 2: CL_CR between 45 and 60 ml/min, group 3: CL_CR between 61 and 80 ml/min and group 4: CL_CR higher than 80 ml/min. Blood samples were collected from each subject before drug administration and at two and eight hours after administration. Individual pharmacokinetic parameters were estimated using a Bayesian approach.
RESULTSMTX concentrations (total and free) were 1.3 to 1.6-times higher in group 1 than in groups 2, 3, and 4. For total and free MTX, t_1/2 eliminations were 22.7 hours in group 1, 13.5 hours in group 2, 12 hours in group 3, and 11 hours in group 4. Clearance of total MTX was 64, 92, 96, 115 ml/min in groups 1 to 4, respectively, it was 118, 163, 171, 206 ml/min in groups 1 to 4 for the free MTX, respectively. Volume of distribution averaged 2.16 l/kg in group 1, 1.92 l/kg in group 2, 1.61 l/kg in group 3, and 1.56 l/kg in group 4. Elimination half life was significantly increased and total clearance was significantly reduced with the degree of renal impairment. Linear regression revealed good correlations between clearance values of MTX and creatinine clearance.
CONCLUSIONIndividual testing is required rather than a general decrease of the MTX dose based only on CL_CR.

Keywords: rheumatoid arthritis; methotrexate; renal insufficiency

---

© 1998 by Annals of the Rheumatic Diseases
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Bateman, J., Penfold, R., Rigby, S. P. (2008). Comment on: Kidney disease in RA patients: prevalence and implication on RA-related drugs management: the MATRIX study. Rheumatology (Oxford) 47: 1259-1259 [Full Text]  
• Karie, S., Gandjbakhch, F., Janus, N., Launay-Vacher, V., Rozenberg, S., Mai Ba, C. U., Bourgeois, P., Deray, G. (2008). Kidney disease in RA patients: prevalence and implication on RA-related drugs management: the MATRIX study. Rheumatology (Oxford) 47: 350-354 [Abstract] [Full Text]  
• Luo, G., Garner, C. E., Xiong, H., Hu, H., Richards, L. E., Brouwer, K. L. R., Duan, J., Decicco, C. P., Maduskuie, T., Shen, H., Lee, F. W., Gan, L.-S. (2007). Effect of DPC 333 [(2R)-2-{(3R)-3-Amino-3-[4-(2-methylquinolin-4-ylmethoxy)phenyl]-2-oxopyrrolidin-1-yl}-N-hydroxy-4-methylpentanamide], a Human Tumor Necrosis Factor {alpha}-Converting Enzyme Inhibitor, on the Disposition of Methotrexate: A Transporter-Based Drug-Drug Interaction Case Study. Drug Metab. Dispos. 35: 835-840 [Abstract] [Full Text]  
• Mita, A. C., Sweeney, C. J., Baker, S. D., Goetz, A., Hammond, L. A., Patnaik, A., Tolcher, A. W., Villalona-Calero, M., Sandler, A., Chaudhuri, T., Molpus, K., Latz, J. E., Simms, L., Chaudhary, A. K., Johnson, R. D., Rowinsky, E. K., Takimoto, C. H. (2006). Phase I and Pharmacokinetic Study of Pemetrexed Administered Every 3 Weeks to Advanced Cancer Patients With Normal and Impaired Renal Function. JCO 24: 552-562 [Abstract] [Full Text]  
• Sweeney, C. J., Takimoto, C. H., Latz, J. E., Baker, S. D., Murry, D. J., Krull, J. H., Fife, K., Battiato, L., Cleverly, A., Chaudhary, A. K., Chaudhuri, T., Sandler, A., Mita, A. C., Rowinsky, E. K. (2006). Two Drug Interaction Studies Evaluating the Pharmacokinetics and Toxicity of Pemetrexed When Coadministered with Aspirin or Ibuprofen in Patients with Advanced Cancer. Clin. Cancer Res. 12: 536-542 [Abstract] [Full Text]  
• Pipitone, N., Kingsley, G. H., Manzo, A., Scott, D. L., Pitzalis, C. (2003). Current concepts and new developments in the treatment of psoriatic arthritis. Rheumatology (Oxford) 42: 1138-1148 [Abstract] [Full Text]  
• Laouari, D., Yang, R., Veau, C., Blanke, I., Friedlander, G. (2001). Two apical multidrug transporters, P-gp and MRP2, are differently altered in chronic renal failure. Am. J. Physiol. Renal Physiol. 280: F636-F645 [Abstract] [Full Text]